ACSL4 and prostate carcinoma: Upon initially treating cells with downregulated ACSL4 using both Panobinostat and RGFP966, we discovered that RGFP966 only partially restored the function of ACSL4 in curbing the proliferation of prostate cancer cells, unlike the significant restoration seen with Panobinostat (Fig. S9B–D).